Clinical Trial Update: EBV-specific Cytotoxic T-lymphocytes (CTLs) for Refractory EBV Infection [Phase 2]

View source ↗

Summary

Phase 2 trial of EBV-specific cytotoxic T-lymphocytes for refractory Epstein-Barr virus infection is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epstein-barr Virus Infections
• Immunodeficiency

Drugs mentioned

• EBV-specific cytotoxic T lymphocytes (EBV-specific cytotoxic T lymphocytes)

Snippet

Sponsor: New York Medical College | Conditions: Epstein-Barr Virus Infections, Primary Immune Deficiency Disorder | Phase 2 | Status: RECRUITING